Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'.
作者信息
Gremese Elisa, Brondani Giovanni, Apollonio Luca, Ferraccioli Gianfranco
机构信息
Department of Medical and Surgical Sciences, Division of Rheumatology, Fondazione Policlinico Universitario A Gemelli IRCCS, Rome, Italy.
Institute of Rheumatology, Università Cattolica del Sacro Cuore.
出版信息
Ann Rheum Dis. 2023 Jan;82(1):e5. doi: 10.1136/annrheumdis-2020-219309. Epub 2020 Nov 3.
Abstract
摘要
相似文献
1
Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'.关于“自身免疫性疾病患者中新型冠状病毒肺炎的患病率及临床结局：一项系统评价与荟萃分析”的通信
Ann Rheum Dis. 2023 Jan;82(1):e5. doi: 10.1136/annrheumdis-2020-219309. Epub 2020 Nov 3.
2
Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'.关于“自身免疫性疾病患者中 COVID-19 的患病率和临床结局：一项系统评价和荟萃分析”的通信
Ann Rheum Dis. 2023 Apr;82(4):e79. doi: 10.1136/annrheumdis-2020-219821. Epub 2021 Jan 15.
3
Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'.
Ann Rheum Dis. 2023 Apr;82(4):e83. doi: 10.1136/annrheumdis-2021-219904. Epub 2021 Jan 27.
4
Response to 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Gremese .
Ann Rheum Dis. 2023 Jan;82(1):e6. doi: 10.1136/annrheumdis-2020-219337. Epub 2020 Nov 3.
5
Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Yang .
Ann Rheum Dis. 2023 Apr;82(4):e80. doi: 10.1136/annrheumdis-2021-219855. Epub 2021 Jan 15.
6
Response to: 'Correspondence on 'Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'' by Lee.
Ann Rheum Dis. 2023 Apr;82(4):e84. doi: 10.1136/annrheumdis-2021-219918. Epub 2021 Jan 27.
7
Correspondence on 'prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis'.
Ann Rheum Dis. 2023 Feb;82(2):e28. doi: 10.1136/annrheumdis-2020-219377. Epub 2020 Nov 10.
8
Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.自身免疫性疾病患者 COVID-19 的患病率和临床结局：系统评价和荟萃分析。
Ann Rheum Dis. 2021 Mar;80(3):384-391. doi: 10.1136/annrheumdis-2020-218946. Epub 2020 Oct 13.
9
Correspondence on 'Acute ischemic stroke outcomes in patients with COVID-19: a systematic review and meta-analysis' by Ferrone .关于费罗内所著《2019冠状病毒病患者的急性缺血性卒中结局：一项系统评价和荟萃分析》的通信
J Neurointerv Surg. 2024 Mar 14;16(4):431-432. doi: 10.1136/jnis-2023-020868.
10
Correspondence to 'Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases'.致《自身免疫性炎性风湿性疾病患者中与 COVID-19 相关的住院风险因素》
Ann Rheum Dis. 2023 Jan;82(1):e1. doi: 10.1136/annrheumdis-2020-218997. Epub 2020 Oct 30.
引用本文的文献
1
Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study.韩国自身免疫性炎性风湿性疾病与新冠病毒疾病结局：一项全国性队列研究
Lancet Rheumatol. 2021 Oct;3(10):e698-e706. doi: 10.1016/S2665-9913(21)00151-X. Epub 2021 Jun 18.
2
The effect of chronic DOAC treatment on clinical outcomes of hospitalized patients with COVID-19.慢性直接口服抗凝药物治疗对 COVID-19 住院患者临床结局的影响。
Int J Clin Pract. 2021 Sep;75(9):e14467. doi: 10.1111/ijcp.14467. Epub 2021 Jun 22.
3
The pathogenesis of microthrombi in COVID-19 cannot be controlled by DOAC: NETosis should be the target.新型冠状病毒肺炎（COVID-19）中微血栓的发病机制无法通过直接口服抗凝剂（DOAC）控制：中性粒细胞胞外诱捕网形成（NETosis）应成为靶点。
J Intern Med. 2021 Mar;289(3):420-421. doi: 10.1111/joim.13228. Epub 2021 Jan 10.
Zotero 插件